Ameriprise’s AMAG Pharmaceuticals AMAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-212,667
Closed -$2M 3888
2020
Q3
$2M Sell
212,667
-17,662
-8% -$168K ﹤0.01% 2668
2020
Q2
$1.76M Sell
230,329
-3,526
-2% -$27K ﹤0.01% 2673
2020
Q1
$1.45M Sell
233,855
-9,210
-4% -$81.1K ﹤0.01% 2645
2019
Q4
$2.96M Buy
243,065
+15,585
+7% +$170K ﹤0.01% 2532
2019
Q3
$2.63M Sell
227,480
-12,455
-5% -$131K ﹤0.01% 2568
2019
Q2
$2.4M Buy
239,935
+7,225
+3% +$77.9K ﹤0.01% 2639
2019
Q1
$3M Buy
232,710
+20,095
+9% +$299K ﹤0.01% 2535
2018
Q4
$3.23M Sell
212,615
-1,335
-0.6% -$25.4K ﹤0.01% 2408
2018
Q3
$4.28M Sell
213,950
-33,790
-14% -$769K ﹤0.01% 2442
2018
Q2
$4.83M Buy
247,740
+47,945
+24% +$1.06M ﹤0.01% 2268
2018
Q1
$4.03M Buy
199,795
+17,660
+10% +$299K ﹤0.01% 2326
2017
Q4
$2.41M Sell
182,135
-3,627
-2% -$54.7K ﹤0.01% 2571
2017
Q3
$3.45M Buy
185,762
+305
+0.2% +$5.68K ﹤0.01% 2334
2017
Q2
$3.41M Buy
185,457
+1,521
+0.8% +$30.1K ﹤0.01% 2335
2017
Q1
$4.15M Buy
183,936
+6,192
+3% +$148K ﹤0.01% 2182
2016
Q4
$6.19M Buy
177,744
+3,237
+2% +$96.7K ﹤0.01% 1863
2016
Q3
$4.28M Sell
174,507
-95,898
-35% -$2.4M ﹤0.01% 2105
2016
Q2
$6.47M Sell
270,405
-136,557
-34% -$3.13M ﹤0.01% 1750
2016
Q1
$9.52M Buy
406,962
+240,178
+144% +$5.7M 0.01% 1449
2015
Q4
$5.04M Sell
166,784
-325,473
-66% -$10.5M ﹤0.01% 2015
2015
Q3
$19.6M Buy
492,257
+312,200
+173% +$19.4M 0.01% 951
2015
Q2
$12.4M Buy
180,057
+93,195
+107% +$5.86M 0.01% 1393
2015
Q1
$4.75M Buy
86,862
+34,784
+67% +$1.66M ﹤0.01% 2137
2014
Q4
$2.22M Buy
52,078
+15,125
+41% +$546K ﹤0.01% 2516
2014
Q3
$1.18M Buy
36,953
+36,923
+123,077% +$787K ﹤0.01% 2718
2014
Q2
$1K Buy
+30
New +$554 ﹤0.01% 5413
2013
Q4
Sell
-1,345
Closed -$29K 5507
2013
Q3
$29K Hold
1,345
﹤0.01% 4161
2013
Q2
$30K Buy
+1,345
New +$29.6K ﹤0.01% 4039

Ameriprise's AMAG Position: Q4 2020 in Review

Ameriprise sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 212,667 shares — an estimated $2M sold.

Ameriprise first reported a position in AMAG in Q2 2013 and held it in 28 quarters. The position peaked at $19.6M in Q3 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.

  • Ameriprise reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Ameriprise sold 212,667 AMAG Pharmaceuticals shares in Q4 2020, an estimated $2M.
  • Ameriprise first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • Ameriprise's AMAG Pharmaceuticals position peaked at $19.6M in Q3 2015.
  • 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.

Based on Ameriprise's 13F filing for Q4 2020, filed 12 Feb 2021.